# Sumanta K. Pal

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/sumanta-k-pal/

## Facts

| Field | Value |
| --- | --- |
| Citations | 34,411 |
| Field | Renal cell carcinoma treatment |
| h-index | 89 |
| i10-index | 461 |
| Last Known Institution | City of Hope |
| OpenAlex ID | https://openalex.org/A5041033274 |
| ORCID iD | https://orcid.org/0000-0002-1712-0848 |
| Works | 1,401 |

## Researcher papers

- [Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma](https://scholariq.org/papers/clinical-activity-and-molecular-correlates-of-response-to-atezolizumab-alone-or/)
- [The International Metastatic Renal Cell Carcinoma Database Consortium model as a prognostic tool in patients with metastatic renal cell carcinoma previously treated with first-line targeted therapy: a population-based study](https://scholariq.org/papers/the-international-metastatic-renal-cell-carcinoma-database-consortium-model-as-a/)
- [Evaluation of Clear Cell, Papillary, and Chromophobe Renal Cell Carcinoma Metastasis Sites and Association With Survival](https://scholariq.org/papers/evaluation-of-clear-cell-papillary-and-chromophobe-renal-cell-carcinoma/)
- [Bladder Cancer, Version 5.2017, NCCN Clinical Practice Guidelines in Oncology](https://scholariq.org/papers/bladder-cancer-version-5-2017-nccn-clinical-practice-guidelines-in-oncology/)
- [Atezolizumab plus cabozantinib versus cabozantinib monotherapy for patients with renal cell carcinoma after progression with previous immune checkpoint inhibitor treatment (CONTACT-03): a multicentre, randomised, open-label, phase 3 trial](https://scholariq.org/papers/atezolizumab-plus-cabozantinib-versus-cabozantinib-monotherapy-for-patients-with/)
- [Identification of a 4-microRNA Signature for Clear Cell Renal Cell Carcinoma Metastasis and Prognosis](https://scholariq.org/papers/identification-of-a-4-microrna-signature-for-clear-cell-renal-cell-carcinoma/)

## Researcher topics

- [Renal cell carcinoma treatment](https://scholariq.org/topics/renal-cell-carcinoma-treatment/)
- [Bladder and Urothelial Cancer Treatments](https://scholariq.org/topics/bladder-and-urothelial-cancer-treatments/)
- [Cancer Immunotherapy and Biomarkers](https://scholariq.org/topics/cancer-immunotherapy-and-biomarkers/)
- [Cancer Genomics and Diagnostics](https://scholariq.org/topics/cancer-genomics-and-diagnostics/)
- [Renal and related cancers](https://scholariq.org/topics/renal-and-related-cancers/)

## Researcher university

- [City of Hope](https://scholariq.org/institutions/city-of-hope/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.